Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

بواسطة Dent, R.A, Lindeman, G.J, Clemons, M, Wildiers, H, Chan, A, McCarthy, N.J, Singer, C.F, Lowe, E.S, Watkins, C.L, Carmichael, J
منشور في 2020